Bank of New York Mellon
GEVA

Bank of New York Mellon’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Bank of New York Mellon’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-124,767
Closed -$12.2M – 4380
2015
Q1 		$12.2M Buy
124,767
+13,582
+12% +$1.44M ﹤0.01% 1839
2014
Q4 		$10.3M Buy
111,185
+1,098
+1% +$86.6K ﹤0.01% 1895
2014
Q3 		$7.57M Buy
110,087
+6,506
+6% +$466K ﹤0.01% 2069
2014
Q2 		$10.9M Sell
103,581
-6,141
-6% -$522K ﹤0.01% 1875
2014
Q1 		$9.1M Buy
109,722
+12,643
+13% +$1.17M ﹤0.01% 1960
2013
Q4 		$6.28M Buy
97,079
+18,762
+24% +$1.11M ﹤0.01% 2161
2013
Q3 		$4.96M Buy
78,317
+7,951
+11% +$391K ﹤0.01% 2255
2013
Q2 		$2.95M Buy
+70,366
New +$3.21M ﹤0.01% 2531

Bank of New York Mellon's GEVA Position: Q2 2015 in Review

Bank of New York Mellon sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 124,767 shares — an estimated $12.2M sold.

Bank of New York Mellon first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $12.2M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Bank of New York Mellon reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Bank of New York Mellon sold 124,767 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $12.2M.
  • Bank of New York Mellon first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Bank of New York Mellon's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $12.2M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Bank of New York Mellon's 13F filing for Q2 2015, filed 6 Aug 2015.